Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 9, 2010, Pages 1569-1578

  Miller, Mark ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Clostridium difficile; Colitis; Diarrhea; Fidaxomicin; OPT 80; Tiacumicin

Indexed keywords

ACAM CDIFF; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERIAL VACCINE; CIPROFLOXACIN; CLOSTRIDIUM DIFFICILE VACCINE; FIDAXOMICIN; IMMUNOLOGIC AGENT; METRONIDAZOLE; NITAZOXANIDE; OP 1118; PROBIOTIC AGENT; RAMOPLANIN; RIFAMPICIN; RIFAXIMIN; TELITHROMYCIN; TIACUMICIN B; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; BACTERIAL COLONIZATION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; FECES ANALYSIS; FECES MICROFLORA; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; INFECTION RISK; INTESTINE ABSORPTION; MULTICENTER STUDY; NONHUMAN; RECURRENT DISEASE; RELAPSE; REVIEW; SINGLE DRUG DOSE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS;

EID: 77952733447     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.485614     Document Type: Review

References (72)

1. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-280
2. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-2449
3. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-2441
4. Hubert B, Loo VG, Bourgault AM, et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis 2007;44:238-244
5. Kuijper EJ, Coignard B, Tull P, et al. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006;12(Suppl 6):2-18
6. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996 - 2003. Emerg Infect Dis 2006;12:409-415
7. Kuijper EJ, Barbut F, Brazier JS, et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 2008;1-7
8. Labbé AC, Poirier L, MacCannell D, et al. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 Strain. Antimicrob Agents Chemother 2008;52:3180-3187
9. Miller M, Gravel D, Mulvey M, et al. and the Canadian Nosocomial Infection Surveillance Program (CNISP). Hospital-acquired Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010;50:194-201
10. Debast SB, van Leengoed LA, Goorhuis A, et al. Clostridium difficile PCR ribotype 078 toxinotype V found in diarrhoeal pigs identical to isolates from affected humans. Environ Microbiol 2009;11:505-511
11. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008;47:1162-1170
12. Bauer MP, Notermans DW, van Benthem BHB, et al. First results of the European Clostridium difficile infection survey (ECDIS) [abstract O86]. 19th European Congress of Clinical Microbiology and Infectious Diseases; 16 - 19 May 2009; Helsinki, Finland
13. O'Neill GL, Beaman MH, Riley TV. Relapse versus reinfection with Clostridium difficile. Epidemiol Infect 1991;107:627-635
14. Johnson S, Adelmann A, Clabots CR, et al. Recurrences of Clostridium difficile not caused by the original infecting organism. J Infect Dis 1989;159:340-343
15. Louie T, Gerson M, Grimard D, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD) [abstract K-425a]. 47th Annual ICAAC; 17 September 2007; Chicago, IL, USA
16. Golan Y, Mullane KM, Miller MA, et al. Low recurrence rate among patients with C. difficile infection treated with fidaxomicin [abstract L1-1639]. 49th ICAAC; 12 - 15 September 2009; San Francisco, CA, USA
17. Mullane KM, Miller MA, Weiss K, et al. Effect of concomitant antibiotics on treatment of Clostridium difficile infection (CDI) with fidaxomicin or vancomycin [abstract LB-14]. 47th Annual Meeting of the Infectious Disease Society of America; 29 October - 1 November 2009; Philadelphia, PA, USA
18. Miller M, Florencio S, Eastmond J, Reynolds S. Results of two prospective randomized studies of Lactobacillus GG (LGG) to prevent C. difficile infection (CDI) in hospitalized adults receiving antibiotics [abstract K-4200]. 48th Annual ICAAC/46th Annual IDSA Meeting; 25 - 28 October 2008; Washington DC, USA
19. Miller M. The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy. Anaerobe 2009;15:281-284
20. Hickson M, D'souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomized double blind placebo controlled trial. BMJ 2007;335:80-84
21. Wilcox M, Sandoe JA. Probiotics and diarrhea: data are not widely applicable. BMJ 2007;335:13
22. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001;69:988-995
23. Aboudola S, Kotloff KL, Kyne L, et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003;71:1608-1610
24. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005;128:764-770
25. US National Institutes of Health. Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection. Available from: http://clinicaltrials.gov/ cta/show/NCT00772343 [Last accessed 23 February 2010]
26. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362:197-205
27. Byker GL, Dinh MT, Gunaratnam NT, et al. Management of Clostridium difficile infection: survey of practices and compliance with national guidelines among primary care physicians. Infect Control Hosp Epidemiol 2009;30:397-399
28. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-307
29. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can Med Assoc J 2004;171:466-472
30. Kuijper EJ, Wilcox MH. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection? Clin Infect Dis 2008;47:63-65
31. Baines SD, O'Connor R, Freeman J, et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008;62:1046-1052
32. Miller M, Bernard L, Thompson M, et al. Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection. Infect Control Hosp Epidemiol (In press)
33. Bauer MP, Kuijper EJ, Van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CD). Clin Microbiol Infect 2009;15:1067-1079
34. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;431-455
35. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983;2:1043-1046
36. Gerber M, Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Expert Opin Investig Drugs 2008;17:547-553
37. Johnson AP. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Curr Opin Investig Drugs 2007;8:168-173
38. Shue Y-K, Du C-JF, Chiou M-H, et al. Tiacumicin production. WO2004014295; 2004
39. Cavalleri B, Arnone A, Di Modugno E, et al. Structure and biological activity of lipiarmycin b. J Antibiotics 1988;41:308-315
40. Theriault RJ, Karwowski JP, Jackson M, et al. Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity. J Antibiotics 1987;40:567-574
41. Hochlowski JE, Swanson SJ, Ranfranz LM, et al. Tiacumicins, a novel complex of 18-membered macrolide antibiotics. II. Isolation and structure determination. J Antibiotics 1987;40:575-588
42. Gualtieri M, Villain-Guillot P, Latouche J, et al. Mutation in the Bacillus subtilis RNA polymerase beta subunit confers resistance to lipiarmycin. Antimicrob Agents Chemother 2006;50:401-402
43. Wosten MMSM. Eubacterial sigma-factors. FEMS Microbiol Rev 1998;22:127-150
44. Finegold SM, Molitoris D, Vaisanen ML, et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004;48:4898-4902
45. Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004;48:4430-4434
46. Ackermann G, Loffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004;48:2280-2282
47. Swanson RN, Hardy DJ, Shipkowitz NL, et al. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother 1991;35:1108-1111
48. Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51:2716-2719
49. Babakhani F, Robert N, Shangle S, et al. Antimicrobial activity and post-antibiotic effect (PAE) of OPT-80, a new macrocyclic compound, against Clostridium difficile [abstract E-2048]. 44th ICAAC; 30 October - 2 November 2004; Washington DC, USA
50. Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 2008;52:4163-4165
51. Babakhani FK, Seddon J, Robert N, et al. Narrow spectrum activity and low fecal binding of OPT-80 and its major hydrolysis metabolite (OP-1118) [abstract E-2076]. 47th ICAAC; 17 - 20 September 2007; Chicago, USA
52. Babakhani F, Seddon J, Robert N, et al. Effect of inoculum, pH, and cations on the in vitro activity of OPT-80 vs Clostridium difficile [abstract D-1648]. 45th ICAAC; 16 - 19 December 2005; Washington DC, USA
53. Babakhani F, Shangle S, Robert N, et al. Resistance development, cross-resistance, and synergy studies of OPT-80 [abstract E-2047]. 44th ICAAC, Washington DC, USA
54. Okumu F, Walsh RB, Sears P, Shue Y-K. Safety and pharmacokinetics of OPT-80, a novel antibiotic for treatment of Clostridium difficile associated diarrhea (CDAD) [abstract F-726]. 44th ICAAC; 30 October - 2 November 2004; Washington DC, USA
55. Louie T, Miller M, Donskey C, et al. Safety, pharmacokinetics and outcomes of PAR-101 in healthy subjects and patients with Clostridium difficile-associated diarrhea (CDAD) [abstract LB2-29]. 45th ICAAC; 16 - 19 December 2005; Washington DC, USA
56. Sears P, Louie TJ, Mullane KM, et al. Pharmacokinetics/pharmacodynamics (PK/PD) of fidaxomicin in treatment of Clostridium difficile infection (CDI) [abstract A1-1949]. 49th ICAAC; 12 - 15 September 2009; San Francisco, CA, USA
57. Shue YK, Sears PS, Shangle S, et al. Safety, tolerance and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 2008;52:1391-1395
58. Louie T, Miller M, Donskey C, et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009;53:223-228
59. Sears P, Babakhani F, Citron DM, et al. Typing and susceptibility of bacterial isolates from the OPT-80 (PAR-101) phase 2A study for C. difficile-associated diarrhea. 9th Biennial Congress of the Anaerobe Society of the Americas; 24 - 27 June 2008; Long Beach, CA, USA
60. Louie TJ, Emery J, Krulicki W, et al. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009;53:261-263
61. Globe NewsWire. Optimer Pharmaceuticals Advances Difimicin Into Phase 3 Clinical Trial. Available from: http://www.globenewswire.com/ newsroom/news.html?d=115459 [Last accessed 9 February 2010]
62. Gerding DN, Sambol SP, Nagaro K, et al. Restriction endonuclease analysis (REA) typing of Clostridium difficile in a phase 3 treatment trial of fidaxomicin vs vancomycin: decreased cure rate for epidemic BI/NAP1/027 strain [abstract L1-1642]. 49th ICAAC; 12 - 15 September 2009; San Francisco, CA, USA
63. Louie TJ, Mullane KM, Weiss K, et al. A randomized, double-blind clinical trial of OPT-80 versus vancomycin in Clostridium difficile infection [abstract O148]. 19th European Congress of Clinical Microbiology and Infectious Diseases; 16 - 19 May 2009; Helsinki, Finland
64. Gorbach S, Weiss K, Sears P, Pullman J. Safety of fidaxomicin versus vancomycin in treatment of Clostridium difficile infection [abstract L1-1640]. 49th ICAAC; 12 - 15 September 2009; San Francisco, CA, USA
65. Nerandzic MM, Mullane K, Miller M, et al. Acquisition and overgrowth of vancomycin-resistant enterococci in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection [abstract K-1915]. 49th ICAAC; 12 - 15 September 2009; San Francisco, CA, USA
66. Miller MA, Mullane KM, Weiss K, et al. Faster time to resolution of diarrhea with fidaxomicin vs. vancomycin in patients with Clostridium difficile infection (CDI) [abstract 422]. 47th Annual Meeting of the Infectious Disease Society of America; 29 October - 1 November 2009; Philadelphia PA, USA
67. Optimer Pharmaceuticals completes enrollment in second fidaxomicin phase 3 clinical trial in patients with Clostridium difficile infection. Available from: http://optimerpharma.com/ news.asp?news-story= 102&page-num=&year= 2009 [Last accessed 4 May 2010]
68. Crook D, Weiss K, Cornely OA, et al. Randomized clinical trial in Clostridium difficile infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin versus vancomycin [abstract LB2401]. 20th European Congress of Clinical Microbiology and Infectious Diseases; 10 - 13 April 2010; Vienna, Austria
69. Berenbaum PL. Oral rifaximin in treatment of Clostridium difficile-associated diarrhea [abstract]. Am J Gastro 2006;101:S199-200
70. Pullman J, Prieto J, Leach TS. Ramoplanin vs vancomycin in the treatment of Clostridium difficile diarrhea: a phase 2 study [abstract K-985a]. 44th ICAAC; 30 October - 2 November 2004; Washington DC, USA
71. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43:421-427
72. Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009;48:e41-6